Medtronic plc, of Dublin, reported financial results for its fiscal year and fourth quarter 2019, with emerging markets growing 12% this quarter, representing 16% of the company's revenue.
Beta Bionics Inc., of Boston, and Copenhagen, Denmark-based Zealand Pharma A/S said the first patients have been dosed in a study evaluating the home use of dasiglucagon in the Ilet bionic pancreas system. The Ilet is a pocket-sized, wearable medical device that autonomously controls blood-sugar levels in diabetics.
Burlingame, Calif.-based Cala Health Inc., which is developing wearable therapies for chronic disease, completed a $50 million series C financing. The funds are earmarked for introducing the Cala Trio for patients with essential tremor and expanding the company's therapeutic pipeline. In addition, Stacy Enxing Seng will join Cala as an independent director and board chair.
Stryker Corp., of Kalamazoo, Mich., reported that the U.S. FDA has given the green light to the Neuroform Atlas stent system, which previously was approved under a humanitarian device exemption (HDE). (See BioWorld MedTech, Nov. 10, 2017.) It is intended for wide-neck, intracranial aneurysms in conjunction with embolic detachable coils.
Palo Alto, Calif.-based startup Symphonyrm reported picking up $10 million in series A financing, led by Adam Street Partners, to help accelerate its growing investment in its artificial intelligence (AI) algorithms and consumer relationship management platform.
Tel Aviv, Israel-based Aidoc Ltd. has received the green light from the U.S. FDA for its pulmonary embolism (PE) product in its suite of artificial intelligence (AI)-based workflow orchestration solutions. Its latest offering aims to help radiologists flag and triage PE cases in chest CTs. The company is looking to cut the time from scan to diagnosis, which could mean for some patients a result in less than five minutes vs. hours – thereby speeding up treatment and improving prognosis.
Rostock, Germany-based Centogene AG has unveiled a 24-month global study to look at the genetic factors in Parkinson's disease (PD), which affects about 1% of individuals older than 60.
Rostock, Germany-based Centogene AG has unveiled a 24-month global study to look at the genetic factors in Parkinson's disease (PD), which affects about 1% of individuals older than 60. Specifically, the Rostock International Parkinson's Disease (ROPAD) study, which will involve up to 10,000 patients, will investigate the genetic background of PD patients for a better understanding of disease development, diagnosis, and treatment.
